AnPac Bio-Medical Science Co

Anpac Bio-Medical Science Co., Ltd., is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in 2010 and is headquartered in Lishui, China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh2 Group Ltd. is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in January 2010 and is headquartered in Lishui, China.

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that Frost & Sullivan Company (“Sullivan”), a leading and well-known US market analysis and research firm has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report (based on data accumulated through the end of 2020), which included next generation cancer screening and detection technologies, including circulating tumor cells (CTCs), circulating-DNA (CT-DNA), exosome, cancer differentiation analysis (CDA), mRNA, and other emerging technologies.  Specifically, for next generation cancer screening and detection, the Sullivan research report ranked AnPac Bio globally as number one in total volume of multi-cancer screening and detection, with 216,600 detection tests, while GRAIL Company was ranked globally number two with 135,100 detection tests.  In the category of volume of commercial multi-cancer tests (for next generation cancer screening and detection), AnPac Bio was ranked global number one as well with 172,900 detection tests.

Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume

PHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2022 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(C) requires companies to maintain a minimum MVPHS of US$15 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the Company for the 30 consecutive business days from December 3, 2021 to January 18, 2022, the Company no longer meets the MVPHS minimum requirement. This notification does not impact the listing and trading of the Company's securities at this time.

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer screening and detection, announced today that on December 30, 2021, the Company's Class III medical device for lung cancer auxiliary diagnosis has completed and passed stringent and rigorous registration tests at the testing laboratory designated by the National Medical Products Administration (NMPA), China's regulatory agent for medical products. China's extensive Class III medical device registration tests included medical device performance tests related to accuracy, precision, stability, linearity, accuracy and repeatability in sample addition, cross-contamination, electromagnetic compatibility (EMC), and reliability and performance under various environmental conditions. Completion of the NMPA registration tests is a significant milestone toward obtaining a Class III medical device registration certificate. Following completion of the registration test, the remaining major step prior to final approval of a registration certificate will be clinical trials which will begin in the first quarter of 2022 with two qualified clinical trial medical institutions.

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022

PHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its joint technical paper on novel Cancer Differentiation Analysis (CDA) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online on November 30, 2021 by the Expert Review of Molecular Diagnostics , a peer-reviewed international medical journal that has an impact factor of 5.2.

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal

PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the nine months ended September 30, 2021. The Company's financial statements and related financial information for the quarter ended September 30, 2021 are unaudited and have not been reviewed by the Company's independent registered accountant. These financial results could differ materially if they were reviewed by the Company's independent registered accountant.

AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%

PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- In its press release dated November 9, 2021 entitled “AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares”, the dollar size of the offering and the number of American Depositary Shares being sold included the exercise of the over-allotment option rather than just the base offering. The expected closing date has been corrected to be November 15, 2021. A corrective press release is below.

CORRECTION -- Anpac Bio, USA

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced the pricing of an underwritten public offering of 1,301,928 of its American Depositary Shares (“ADSs”) at a public offering price of $2.22 per share, for gross proceeds to the Company of approximately $2.9 million, before deducting the underwriting discount and other offering expenses payable by the Company. This includes the full exercise of the underwriter's over-allotment option.

AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”). EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering.

UPDATE - AnPac Bio Commences Proposed Public Offering of American Depositary Shares

SUNRISE, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”). EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering.

AnPac Bio Commences Proposed Public Offering of American Depositary Shares

Philadelphia, Pennsylvania--(Newsfile Corp. - November 8, 2021) - Anpac Bio (NASDAQ: ANPC) today announced that Phil Case, Head of Investor Relations | PR will be attending the Q4 Virtual Investor Summit. Learn how Anpac Bio is democratizing early cancer screening and detection. Current methods for early cancer screening and detection have limited clinical utility and average to non-existent performance for early cancer screening and detection, which is critical for reducing cancer related mortality.AnPac Bio has...

Anpac Bio Invites You to Join Us at the Q4 Virtual Investor Summit

Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases

AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases

PHILADELPHIA, Oct. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2021.

AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3%

PHILADELPHIA, Sept. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC (“Nasdaq”) dated September 24, 2021 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(A) requires companies to maintain a minimum market value of US$50,000,000 and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company for the 30 consecutive business days from August 12, 2021 to September 23, 2021, the Company no longer meets the minimum market value requirement. This notification does not impact the listing and trading of the Company's securities at this time.

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Deficiency

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd.

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase In Subsidiary Holding

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021.

AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%

PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory results, inspectors examine the laboratory's records and quality control of the procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.

AnPac Bio's USA Laboratory Receives Accreditation from the College of American Pathologists

PHILADELPHIA, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announces that the Company filed with China's National Medical Products Administration (NMPA) on Aug. 19, 2021, for registration testing of its class III, multi-cancer detection medical device based on its Cancer Differentiation Analysis Technology (CDA).

AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device

PHILADELPHIA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announces that it has hired Dr. Sunil Pandit, a successful life sciences veteran and highly accomplished bio-medical scientist, as its U.S. CEO, effective Aug. 16, 2021. In his new role, Dr. Pandit will lead AnPac Bio's U.S. R&D and commercialization efforts to drive adoption and growth of AnPac's Cancer Differentiation Analysis (CDA) technology, the company's core product for cancer screening and early detection.

AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO

PHILADELPHIA, Aug. 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that Announced that AnPac Bio and Roche Pharmaceuticals China (“Roche”) have entered into a cooperation agreement to explore novel healthcare and medical solutions and collaboration models in early cancer screening, early diagnosis, and early treatment, through leveraging both parties' advantages and sources.

AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions

Independent Director has Strong Track Record at US Fortune 500 Companies Independent Director has Strong Track Record at US Fortune 500 Companies

AnPac Bio Announces Appointment of New Independent Director

Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations

AnPac Bio Began Generating Contract Medical Device R&D Revenue

AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) has announced strong growth in test volume in 1H of 2021. The total number of paid customers and testing volume increased almost 110% compared with 1H of 2020.

AnPac Bio Stock Gains On Robust Growth In Commercial Testing Volume In Q2

PHILADELPHIA, July 20, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, pre-announced today that it has experienced strong growth in test volume in the first half year of 2021, with total number of paid customers and testing volume increasing almost 110% compared with the same period in 2020. In addition, in Q2 of this year, the Company's total paid tests and paid cancer tests increased approximately 280% and approximately 270%, respectively (quarter over quarter). In addition to paid cancer tests, other tests including new test products launched in 2020 have also grown.

AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1

AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) has received its first disease treatment patent by the United States Patent and Trademark Office. The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.

AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent

Pieris Pharma

Sesen Bio Inc.

Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?

News for AnPac Bio-Medical Science Co Stock (ANPC)